Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF) Supplemental Material Index Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Thompson, B. J. Articles by Aifantis, I. Search for Related Content PubMed PubMed Citation Articles by Thompson, B. J. Articles by Aifantis, I. Related Collections Related Article Social Bookmarking                      What's this?

¹ Department of Pathology, ² New York University Cancer Institute, New York University School of Medicine, New York, NY 10016
³ Medical Scientist Training Program, Committee on Immunology, University of Chicago, Chicago, IL 60637
⁴ Institute for Cancer Genetics, Columbia University, New York, NY 10032
⁵ Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611
⁶ Hemato-Oncology Laboratory, Department of Pediatrics, University of Padova, 35122 Padova, Italy

CORRESPONDENCE Iannis Aifantis: iannis.aifantis{at}med.nyu.edu

Recent studies have shown that activating mutations of NOTCH1 are responsible for the majority of T cell acute lymphoblastic leukemia (T-ALL) cases. Most of these mutations truncate its C-terminal domain, a region that is important for the NOTCH1 proteasome-mediated degradation. We report that the E3 ligase FBW7 targets NOTCH1 for ubiquitination and degradation. Our studies map in detail the amino acid degron sequence required for NOTCH1–FBW7 interaction. Furthermore, we identify inactivating FBW7 mutations in a large fraction of human T-ALL lines and primary leukemias. These mutations abrogate the binding of FBW7 not only to NOTCH1 but also to the two other characterized targets, c-Myc and cyclin E. The majority of the FBW7 mutations were present during relapse, and they were associated with NOTCH1 HD mutations. Interestingly, most of the T-ALL lines harboring FBW7 mutations were resistant to -secretase inhibitor treatment and this resistance appeared to be related to the stabilization of the c-Myc protein. Our data suggest that FBW7 is a novel tumor suppressor in T cell leukemia, and implicate the loss of FBW7 function as a potential mechanism of drug resistance in T-ALL.

Abbreviations used: AML, acute myeloid leukemia; DN, dominant-negative; GSI, -secretase inhibitors; HD, heterodimerization; T-ALL, T cell acute lymphoblastic leukemia.

B.J. Thompson and S. Buonamici contributed equally to this paper.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article

New mutations stabilize NOTCH1

Hema Bashyam
J. Exp. Med. 2007 204: 1733b. [Full Text] [PDF]

This article has been cited by other articles:

• Rizzo, P., Miao, H., D'Souza, G., Osipo, C., Yun, J., Zhao, H., Mascarenhas, J., Wyatt, D., Antico, G., Hao, L., Yao, K., Rajan, P., Hicks, C., Siziopikou, K., Selvaggi, S., Bashir, A., Bhandari, D., Marchese, A., Lendahl, U., Qin, J.-Z., Tonetti, D. A., Albain, K., Nickoloff, B. J., Miele, L. (2008). Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches. Cancer Res. 68: 5226-5235 [Abstract] [Full Text]  
• Grim, J. E., Gustafson, M. P., Hirata, R. K., Hagar, A. C., Swanger, J., Welcker, M., Hwang, H. C., Ericsson, J., Russell, D. W., Clurman, B. E. (2008). Isoform- and cell cycle-dependent substrate degradation by the Fbw7 ubiquitin ligase. J. Cell Biol. 181: 913-920 [Abstract] [Full Text]  
• Thompson, B. J., Jankovic, V., Gao, J., Buonamici, S., Vest, A., Lee, J. M., Zavadil, J., Nimer, S. D., Aifantis, I. (2008). Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J. Exp. Med. 205: 1395-1408 [Abstract] [Full Text]  
• Matsuoka, S., Oike, Y., Onoyama, I., Iwama, A., Arai, F., Takubo, K., Mashimo, Y., Oguro, H., Nitta, E., Ito, K., Miyamoto, K., Yoshiwara, H., Hosokawa, K., Nakamura, Y., Gomei, Y., Iwasaki, H., Hayashi, Y., Matsuzaki, Y., Nakayama, K., Ikeda, Y., Hata, A., Chiba, S., Nakayama, K. I., Suda, T. (2008). Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev. 22: 986-991 [Abstract] [Full Text]  
• Balgobind, B. V., Van Vlierberghe, P., van den Ouweland, A. M. W., Beverloo, H. B., Terlouw-Kromosoeto, J. N. R., van Wering, E. R., Reinhardt, D., Horstmann, M., Kaspers, G. J. L., Pieters, R., Zwaan, C. M., Van den Heuvel-Eibrink, M. M., Meijerink, J. P. P. (2008). Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 111: 4322-4328 [Abstract] [Full Text]  
• Staal, F. J.T., Langerak, A. W. (2008). Signaling pathways involved in the development of T-cell acute lymphoblastic leukemia. haematol 93: 493-497 [Full Text]  
• De Keersmaecker, K., Lahortiga, I., Mentens, N., Folens, C., Van Neste, L., Bekaert, S., Vandenberghe, P., Odero, M. D., Marynen, P., Cools, J. (2008). In vitro validation of {gamma}-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. haematol 93: 533-542 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS